AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02922335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
Study NCT03851562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil 20 micrograms
Description: Intravenous infusion of PGE1 (Days 0, +1 and +2)
Study NCT03851562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of physiological saline solution
Study NCT02804295 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collaborative Care Intervention
Description: All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
Study NCT03863821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC
Description: HHHFNC setting:~1. Flow rate: 40L/min~2. FiO2: 0.4~HHHFNC will use immediately before 6MWT and remove at the end of 6MWT
Study NCT01735136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: InSan Bamboo Salt
Description: InSan Bamboo Salt (10g/day)
Study NCT02881684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration Therapy (AspireAssist®)
Description: Use of the AspireAssist device in aspiration therapy
Study NCT02881684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration Therapy (AspireAssist®)
Description: Use of the AspireAssist device in aspiration therapy
Study NCT04459949 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sharkskin
Description: Use of Sharkskin ILM forceps
Study NCT02881684 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Therapy
Description: Lifestyle therapy is a behavioral, diet and physical activity education program
Study NCT02881684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Therapy
Description: Lifestyle therapy is a behavioral, diet and physical activity education program
Study NCT03370640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-363856
Description: An oral 25 or 50mg dose of SEP 363856
Study NCT02585908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK
Description: CIK cells will be used against tumor cells.
Study NCT02585908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T
Description: γδ T cells will be used against tumor cells.
Study NCT02585908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK and γδ T
Description: CIK and γδ T cells will be used against tumor cells.
Study NCT02138877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: After coming stent after dismembered pyeloplasty
Description: Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
Study NCT02138877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stentless dismembered pyeloplasty
Description: Dismembered pyeloplasty through lumbar incision. No stents are inserted
Study NCT01228058 — intervention group
Intervention type: PROCEDURE
Intervention: RapidTEG test
Description: The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
Study NCT04122521 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI
Study NCT01924689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium novyi-NT spores
Description: Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
Study NCT00739752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed-Recommended
Description: Subjects receive loss-framed messages and are recommended the vaccine.
Study NCT04413578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Continuous Glucose Monitor that, after applied, sends continuous glucose readings to to the patient's smartphone every 5 minutes. This allows the patients to receive more readings over a 24 hour period versus standard of care glucometer finger sticks.
Study NCT04413578 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Contour NextOne
Description: A Standard of Care Glucometer with Bluetooth capability. The patient inserts a test strip into the device, takes a finger stick and collects a small blood sample on the tip of the strip to initiate the device to detect a glucose reading.
Study NCT02745964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA supreme
Description: Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
Study NCT02745964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
Study NCT01825408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
Study NCT01825408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
Study NCT01825408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmentin
Description: If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
Study NCT02149342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexylaminolaevulinate cream
Description: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
Study NCT02149342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylaminolaevulinate cream
Description: MAL 16% is used as photosensitizer for daylight-PDT
Study NCT01331694 — intervention group
Intervention type: DRUG
Intervention: fluticasone/salmeterol combination (FSC) 250/50mcg
Description: patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
Study NCT01331694 — intervention group
Intervention type: DRUG
Intervention: tiotropium
Description: patients initiating treatment with tiotropium
Study NCT01331694 — intervention group
Intervention type: DRUG
Intervention: ipratropium bromide alone or in fixed dose combination with albuterol
Description: patients initiating treatment with ipratropium/albuterol
Study NCT04138615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Study NCT04138615 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
Study NCT03493334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual feedback
Description: Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
Study NCT03493334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No visual feedback
Description: Participants will be asked to perform active movements of their neck with the mirrors covered.
Study NCT01735136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (10g/day)
Study NCT02808559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodystudio ATBM (Automatic Total Body Mapping)
Description: The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
Study NCT02277665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CUD Treatment
Study NCT02277665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CUD Treatment
Study NCT02277665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment
Study NCT03704285 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
Study NCT03704285 — intervention group
Intervention type: DEVICE
Intervention: BIS
Description: GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
Study NCT01856816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Pattern Treatment A
Description: In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals.
Study NCT00761969 — intervention group
Intervention type: OTHER
Intervention: Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice
Description: Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
Study NCT02261558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Improvisation Instrumental Music Therapy
Description: Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
Study NCT02261558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Vocal Improvisation
Description: \* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
Study NCT00977171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
Study NCT01727596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: taping
Description: Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
Study NCT00412893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
Study NCT00412893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
Study NCT03833869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Description: Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
Study NCT02737475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986178
Description: Specified dose on specified days
Study NCT02737475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02737475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT04335513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early CGM-guided education and initiation of insulin therapy.
Description: Careful monitoring of children progressing from stage 2 to stage 3 T1D using continuous glucose monitor (CGM) technology, staged education targeted to assist families in recognizing evolving dysglycemia, and addressing glycemic abnormalities with early initiation of insulin can substantially reduce the HbA1c and risk of DKA at diagnosis, thereby changing the trajectory of the disease course.
Study NCT04335513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care: glucometer surveillance and basic education.
Description: * Usual education and advice on glycemic surveillance based on protocols of TEDDY/DAISY/ASK.~* Blinded CGM for 10 days every 3 months to collect data on glycemic profile with basic feedback regarding changes.
Study NCT03221647 — intervention group
Intervention type: OTHER
Intervention: Intestinal biopsies
Description: Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
Study NCT00942084 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acyclovir
Description: Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).
Study NCT04459949 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Grieshaber
Description: Use of Grieshaber ILM forceps
Study NCT01478256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Topical erythromycin ointment twice a day
Study NCT01478256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifloxocin
Description: Topical Besifloxocin twice a day
Study NCT02458794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: function tests
Description: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
Study NCT02458794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA SupremeTM
Study NCT00942084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days).
Study NCT03667040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JOOL app
Description: Participants will use the JOOL app for 30 days
Study NCT01710787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: 3 unilateral intranasal sprays per dose
Study NCT01710787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3%
Description: 3 unilateral intranasal sprays per dose
Study NCT01710787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 unilateral intranasal sprays per dose
Study NCT01856816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Pattern Treatment B
Description: In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals.
Study NCT01856816 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Meal Pattern Treatment C
Description: In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals.
Study NCT01336686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: Arhalofenate 400 mg once daily for 4 weeks
Study NCT01336686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: Arhalofenate 600 mg once daily for 4 weeks
Study NCT01336686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Matching placebo once daily for 4 weeks
Study NCT02737475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus vaccine
Description: Specified dose on specified days
Study NCT02737475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPV-001 vaccine
Description: DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
Study NCT02737475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT03147352 — intervention group
Intervention type: DEVICE
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
Study NCT02279667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: oral suspension 50 mg/mL
Study NCT01311531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and fixation with TriMed fragment-specific system
Description: Anatomical reduction, achieved by the open technique.
Study NCT01311531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction and fixation with TriMed volar locking plate
Description: Anatomical reduction, achieved by the open technique.
Study NCT02179580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xiang-Sha-Liu-Jun-Zi-Tang
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
Study NCT02179580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiang-Sha-Liu-Jun-Zi-Tang
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
Study NCT02179580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
Study NCT02179580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
Study NCT02765906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphic card
Description: A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics \& Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
Study NCT02765906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
Study NCT00785252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered Intraosseous device (EZIO)
Description: EZIO
Study NCT00785252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard central line
Description: placement of a central line
Study NCT04590482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg each 12 hours for 2 days followed by vaginal misoprostol 800 mcg for induction of abortion
Study NCT01298232 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Cardiophonogram
Description: Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
Study NCT01868802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
Study NCT01868802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline at 0.9% intravenous infusion will be administered over 40 minutes.
Study NCT04590482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion